RecruitingNAINTERVENTIONAL

Study on the Contribution of the Genetic Tumor Profile Obtained by Circulating Tumor DNA Analysis in the Multidisciplinary Molecular Biology Meeting of Eastern PACA

This study is designed to see how effective a new type of blood test, called a liquid biopsy, is at finding genetic changes in different cancers. Doctors usually find these changes by taking a small piece of the tumour (a solid biopsy). This new blood test, however, only requires a simple blood sample. We want to see if the liquid biopsy can give doctors helpful information that guides treatment decisions, just like the traditional solid biopsy does. The study involves giving a blood sample for this test and comparing its results to what we already know from tissue samples. This research aims to improve how we identify cancer characteristics and help doctors choose the best care for patients with advanced cancer.

At a glance

Status

Recruiting

Phase

Sponsor

Centre Antoine Lacassagne

Enrolment target

238

Start

03 Mar 2025

Estimated completion

03 Jun 2027

Neoplasm Malignant

What is this study about?

This study is about a new way to understand advanced cancer called a "liquid biopsy." Normally, to find out about a cancer's specific genetic makeup, doctors need to take a small piece of the tumour itself, which is called a "solid biopsy." This can sometimes be a difficult procedure for patients.

However, a liquid biopsy is a much simpler blood test. It looks for tiny bits of cancer cells that break off and float around in your blood. By analysing these bits, doctors hope to get information about the cancer's genetic changes, which are important for choosing the right treatments. This study will compare how well the liquid biopsy works compared to the traditional solid biopsy, to see if it can provide similar, useful information.

The main goal is to see if this blood test can help doctors get a clearer picture of a patient's cancer so they can make better, more personal treatment plans without always needing an invasive tissue biopsy. This could potentially make it easier and more comfortable for patients to get the information needed for their care.

Key takeaways

This study evaluates a new blood test (liquid biopsy) for cancer.
It compares the blood test to traditional tissue biopsies for finding cancer changes.
The goal is to improve how doctors get information about cancer.
Participation involves providing a blood sample.
No new medications are given as part of this study.
Results won't change your immediate treatment, but could help future patients.

Who may be eligible?

To join this study, you need to be at least 18 years old and have an advanced cancer that doctors are treating with the aim of controlling it, not curing it. You also need to have had your case discussed by a special team of cancer experts who look at molecular information. We also need to have either a previous tissue sample of your cancer from within the last 5 years, or it must be possible to take a new small tissue sample.

There are also some reasons why you might not be able to join. For example, if you've had another cancer diagnosed or treated recently (within the last 5 years), or if you have a serious ongoing health condition. People who are pregnant, breastfeeding, or unable to give their informed consent are also not able to take part.

Could this study suit you?

Answer these quick questions to see if you may be eligible. This is a guide only — the research team makes the final call.

Are you 18 years old or older?
Do you have an advanced cancer that is being managed, not cured?
Has your cancer case been discussed by a special team of experts?
Do you have a cancer tissue sample from the last 5 years, or can one be taken?
Are you able to provide informed consent?
Are you *not* pregnant or breastfeeding?

Answer every question to see your result.

What does participation involve?

If you decide to take part in this study, the main thing you would need to do is provide a blood sample. This blood sample would be used for the new liquid biopsy test. The study will then compare the results from this blood test with information already known about your cancer from previous tissue samples. There are no new medications given as part of this study. The total time you would be involved in the study would mostly revolve around providing that blood sample and allowing researchers to compare the data, but it wouldn't involve regular long-term follow-up visits specifically for the study itself beyond your usual medical care.

Potential risks and benefits

Taking part in this study could potentially help advance our understanding of how to use liquid biopsies to guide cancer treatment, which might benefit future patients. For you personally, there is no direct medical benefit as the liquid biopsy results won't immediately change your current treatment plan in this study. The main risk involved is the minor discomfort and very small chance of bruising or infection from having a blood sample taken, which is a routine procedure. You are free to withdraw from the study at any time without it affecting your usual medical care.

Locations (1)

Centre Antoine Lacassagne
Verified postcode
Nice, France· Recruiting

Common questions

What is a 'liquid biopsy'?

A liquid biopsy is a blood test that looks for tiny pieces of cancer cells in your blood to learn about your cancer's genetic makeup.

Will this study change my cancer treatment?

No, this study is for research purposes. The results from the liquid biopsy won't directly change your treatment during the study period.

Do I need to take new medication for this study?

No, this study does not involve any new medications. You will only be asked to provide a blood sample.

What is the 'Multidisciplinary Molecular Biology Meeting'?

This is a meeting where a team of cancer doctors and experts discuss individual patient cases to plan the best care based on detailed molecular information about the cancer.

Can I leave the study if I change my mind?

Yes, you can withdraw from the study at any time without it affecting your medical care.

How to find out more

Study coordinator

drci-promotion@nice.unicancer.fr +33 04 92 03 14 76 Official trial record

Always speak to your GP or specialist before deciding to take part in a study.